The global pain therapeutic injectables market holds a valuation of US$ 19.3 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 19.3 Billion |
| Market Value 2033 | US$ 30.9 Billion |
| CAGR 2023 to 2033 | 4.5% |
| Market Share of Top 5 Countries | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Therapeutic injections for treating pain can aid in reducing swelling and discomfort. Depending on the location, muscle injury, skeletal or neurological structures, and overall symptoms, there are choices for injectable treatment for almost any sort of pain a patient is experiencing. These injections can be administered intravenously, subcutaneously, or through an epidural catheter. These injectables are frequently used to treat acute pain which occurs because of injuries, post-operative pain, or chronic pain due to any kind of illness.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market holds around 28.5% share of the overall global painkillers market with a value of around US$ 67.7 Billion, in 2022.
The increasing prevalence of chronic pain conditions, such as arthritis, cancer pain, and lower back pain, is one of the primary drivers of the pain therapeutic injectables market. These conditions require long-term pain management, which often includes the use of injectable pain medications. Due to the rise in chronic diseases, the market for pain therapeutic injectables has exhibited a consistent increase.
Apart from this, the market is anticipated to expand in the coming years because of the rising number of surgeries performed worldwide. This eventually demands post-operative pain management. Moreover, technological developments have led to improvements in drug delivery systems which ensures more accurate and effective administration of injectable drugs.
As the importance of pain management becomes more widely recognized, patients are seeking out effective pain relief options that can improve their quality of life. Pain therapeutic injectables are one such option that can provide rapid and effective relief from pain.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 30.9 billion in the year 2033.
There are numerous potentials for innovation and expansion in the market for companies dealing in pain therapeutic injectables. The market is being driven by the rising demand for minimally invasive procedures worldwide. Minimally invasive procedures, such as injections, are becoming increasingly popular among patients due to their ability to reduce pain and discomfort while minimizing the risk of complications. This is driving the demand for pain therapeutic injectables, which can provide effective pain relief with minimal invasiveness. The development of this market is anticipated to be aided by a number of new technologies and therapies. Due to their efficiency and patient convenience, injectable pain treatments are anticipated to see increased use.
As the global population ages, the prevalence of chronic pain conditions is expected to increase, which will drive demand for pain therapeutic injectables. The geriatric population is particularly susceptible to chronic pain, making them a key demographic for the pain therapeutic injectables market.
Principal Consultant
The market is constrained by a number of factors, including expensive injectable drug costs, adverse effects from prolonged use of opioids, and the possibility of drug abuse and addiction. Pain therapeutic injectables can be expensive, which can limit access for some patients. This is particularly true for those who do not have adequate health insurance coverage or who are underinsured.
The regulatory environment is also posing difficulties for the market, particularly when it comes to confirming the efficacy and safety of new injectable treatments before they can be released. The development and approval of new pain medications can be a lengthy and expensive process due to the strict regulatory requirements in many countries. This can limit the number of new products entering the market and slow down innovation.
The USA dominates the global region with a total market share of around 39.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
The market for pain therapeutic injectables in the USA is expanding due to a number of factors. One of the contributing aspects is the increasing prevalence of chronic pain. Chronic pain is a major healthcare issue in the United States, affecting millions of people each year. This has led to a growing demand for pain management therapies, including pain therapeutic injectables.
Other than this, an increase in awareness and education regarding the advantages of injectable painkillers such as their quicker onset of action and more accurate dosing, among medical professionals and patients, is driving the market in this region. In USA, the growth of the market is also fueled by the creation of novel and sophisticated injectable medications as well as the increased availability of enhanced delivery methods. These advancements are driving growth in the market by providing better treatment options for patients.
Japan contributed around US$ 1.1 Billion revenue to the global pain therapeutic injectables market in 2022. The prevalence of chronic pain conditions is increasing in Japan, including osteoarthritis, cancer pain, and lower back pain. This has led to a growing demand for pain therapeutic injectables. Additionally, as older people are more likely to have chronic pain, Japan's aging population is fueling the demand for pain management therapies, including pain therapeutic injectables.
The development of this market has also been aided by technological developments and the accessibility of new painkillers and treatments in Japan. The demand for pain treatment injectables in Japan has also been significantly influenced by patients' and healthcare professionals' growing knowledge regarding the importance of effective pain management.
Germany held a market share of 25.6% in the Western Europe pain therapeutic injectables market in 2022.
The market is expanding in Germany due to the growing popularity of minimally invasive procedures for pain management, which frequently involves the use of injectable medications. Other than this, the demand for pain treatment injectables in the nation is also being fueled by the growing importance of at-home healthcare and self-administration of injectables. Overall, it is anticipated that these factors will continue to fuel the market for pain therapeutic injectables in Germany in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Opioids by drug class segment held 53.4% share in the global market in 2022. Opioids are still frequently used to control pain, especially in situations where there is significant acute pain or chronic pain that does not respond to other forms of treatment. In recent years, although there has been a shift towards the use of non-opioid options for pain management, opioids still have a place in some circumstances. Overall, opioids play a substantial role in the market of therapeutic injectables for treating pain, but their usage needs to be carefully regulated and balanced with other therapies.
Prescription drugs by product segment contributed around US$ 11.3 Billion in the global market in 2022. Since they are frequently used to manage pain in individuals who require more intense therapy, prescription medications play a key role in the market of therapeutic injectables for treating pain. The market for pain therapeutic injectables also has a prescription medicine sector that is significant because it offers healthcare professionals a variety of treatment alternatives to fulfill the various demands of their patients.
Surgical pain by indication segment held more than one-third revenue share in the global market in 2022. Injectable painkillers are in high demand because of the increasing prevalence of surgical pain conditions. As a result of tissue damage and inflammation, patients who have undergone surgery, are most likely to experience pain so, pain treatment is a crucial component of post-operative care. Since pain therapeutic injectables can offer more immediate and intense pain relief than oral drugs, these are often utilized to alleviate the discomfort due to the pain.
Retail pharmacies is the leading segment with over 27.0% revenue share in 2022 globally. When it comes to distribution channel, retail pharmacies are considered a place which is quite accessible to patients in order to buy these kinds of injectable drugs. Therefore, retail pharmacies play a significant role in this market. Retail pharmacies typically stock a wide range of medications, including prescription drugs, over-the-counter medications, and other healthcare products. This makes it easy for patients to find the medications they need without having to visit multiple locations.
Key differentiating tactics used by producers of pain therapeutic injectables include an increase in product releases and regulatory body approval, growth into other regions, and marketing approvals in other locations. The dynamics of the market have changed as a result of increasing awareness.
Similarly, recent developments related to companies manufacturing pain therapeutic injectables have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Central Asia, Russia & Belarus, Balkan & Baltic Countries, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia & New Zealand, Japan, China, South Korea, GCC Countries, Kingdom of Saudi Arabia, Türkiye, Northern Africa, South Africa, and Israel |
| Key Market Segments Covered | Drug Class, Product, Indication, Distribution Channel and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The United States, Japan, and China dominate the global pain therapeutic injectables market.
The pain therapeutic injectables market is forecast to register a CAGR of 4.5% through 2033.
The overall global painkillers market has a value of around US$ 19.3 Billion in 2022.
Technological advancement disrupts the current market trends, such as the development of new pain medications and delivery methods.
The global market size of pain therapeutic injectables is to reach US$ 30.9 Billion by 2033.
1. Executive Summary | Pain Therapeutic Injectables Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Patient Treatment Journey 4.2. Disease Epidemiology 4.3. Pipeline Assessment 4.3.1. By Drug Class 4.3.2. Comprehensive Assessment by Phases 4.3.3. Emerging Novel Trends 4.4. List of Key Players, By Region 4.5. Number of Surgeries Performed, By Region 4.6. Key Regulations 4.7. Reimbursement Landscape 4.8. PESTLE Analysis 4.9. Value chain analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Painkillers Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increasing Aging Population 5.2.3. Patent Expiration of Novel Pain Management Drugs (Opioids) 5.2.4. Introduction of Novel Advancements in Pain Therapeutics Injectables 5.2.5. Average Annual Spending on Pain Therapeutics Injectables 5.2.6. Awareness of Pain Therapeutics 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. 2022 Market Scenario 6.2. COVID-19 and Impact Analysis 6.2.1. By Drug Class 6.2.2. By Product 6.2.3. By Indication 6.2.4. By Distribution Channel 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 8.3.1. Opioids 8.3.1.1. Tramadol 8.3.1.2. Oxycodone 8.3.1.3. Hydrocodone 8.3.1.4. Other Opioids 8.3.2. NSAIDs 8.3.3. Local Anesthetics 8.3.4. Acetaminophen 8.4. Market Attractiveness Analysis By Drug Class 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Over-The-Counter (OTC) Products 9.3.2. Prescription Drugs 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 10.3.1. Surgical Pain 10.3.2. Cancer Pain 10.3.3. Neuropathic Pain 10.3.4. Musculoskeletal & Joint Pain 10.3.5. Others 10.4. Market Attractiveness Analysis By Indication 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 11.3.1. Hospital Pharmacies 11.3.2. Specialty Clinics 11.3.3. Long Term Care Centers 11.3.4. Retail pharmacies 11.3.5. Drug Stores 11.3.6. Online Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 12.2. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 12.2.1. North America 12.2.2. Latin America 12.2.3. Western Europe 12.2.4. Eastern Europe 12.2.5. Russia & Belarus 12.2.6. Balkan & Baltic Countries 12.2.7. South Asia & Pacific 12.2.8. East Asia 12.2.9. Central Asia 12.2.10. Middle East & Africa 12.3. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Drug Class 13.3.3. By Product 13.3.4. By Indication 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Product 13.4.4. By Indication 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis & Forecast 13.7.1. USAMarket 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Drug Class 13.7.1.2.2. By Product 13.7.1.2.3. By Indication 13.7.1.2.4. By Distribution Channel 13.7.2. Canada Market 13.7.3. Introduction 13.7.4. Market Analysis and Forecast by Market Taxonomy 13.7.4.1.1. By Drug Class 13.7.4.1.2. By Product 13.7.4.1.3. By Indication 13.7.4.1.4. By Distribution Channel 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Product 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Product 14.4.4. By Indication 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. Brazil Market 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Drug Class 14.7.1.2.2. By Product 14.7.1.2.3. By Indication 14.7.1.2.4. By Distribution Channel 14.7.2. Mexico Market 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Drug Class 14.7.2.2.2. By Product 14.7.2.2.3. By Indication 14.7.2.2.4. By Distribution Channel 14.7.3. Argentina Market 14.7.4. Introduction 14.7.5. Market Analysis and Forecast by Market Taxonomy 14.7.5.1.1. By Drug Class 14.7.5.1.2. By Product 14.7.5.1.3. By Indication 14.7.5.1.4. By Distribution Channel 15. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. France 15.3.1.3. Spain 15.3.1.4. Italy 15.3.1.5. BENELUX 15.3.1.6. Nordic Countries 15.3.1.7. United Kingdom 15.3.2. By Drug Class 15.3.3. By Product 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Product 15.4.4. By Indication 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Germany Painkillers Market 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Drug Class 15.7.1.2.2. By Product 15.7.1.2.3. By Indication 15.7.1.2.4. By Distribution Channel 15.7.2. France Market 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Drug Class 15.7.2.2.2. By Product 15.7.2.2.3. By Indication 15.7.2.2.4. By Distribution Channel 15.7.3. Spain Market 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Drug Class 15.7.3.2.2. By Product 15.7.3.2.3. By Indication 15.7.3.2.4. By Distribution Channel 15.7.4. Italy Market 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Drug Class 15.7.4.2.2. By Product 15.7.4.2.3. By Indication 15.7.4.2.4. By Distribution Channel 15.7.5. BENELUX Market 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Drug Class 15.7.5.2.2. By Product 15.7.5.2.3. By Indication 15.7.5.2.4. By Distribution Channel 15.7.6. Nordic Countries Market 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Drug Class 15.7.6.2.2. By Product 15.7.6.2.3. By Indication 15.7.6.2.4. By Distribution Channel 15.7.7. UNITED KINGDOMMarket 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Drug Class 15.7.7.2.2. By Product 15.7.7.2.3. By Indication 15.7.7.2.4. By Distribution Channel 16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1.1. Poland 16.3.1.1.2. Hungary 16.3.1.1.3. Romania 16.3.1.1.4. Czech Republic 16.3.1.1.5. Rest of Eastern Europe 16.3.2. By Drug Class 16.3.3. By Product 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Drug Class 16.4.2. By Product 16.4.3. By Indication 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. Poland Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Drug Class 16.7.1.2.2. By Product 16.7.1.2.3. By Indication 16.7.1.2.4. By Distribution Channel 16.7.2. Hungary Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Drug Class 16.7.2.2.2. By Product 16.7.2.2.3. By Indication 16.7.2.2.4. By Distribution Channel 16.7.3. Romania Market 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Drug Class 16.7.3.2.2. By Product 16.7.3.2.3. By Indication 16.7.3.2.4. By Distribution Channel 16.7.4. Czech Republic Market 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Drug Class 16.7.4.2.2. By Product 16.7.4.2.3. By Indication 16.7.4.2.4. By Distribution Channel 17. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. I India 17.3.1.2. Indonesia 17.3.1.3. Thailand 17.3.1.4. Philippines 17.3.1.5. Malaysia 17.3.1.6. Vietnam 17.3.1.7. Rest of SA 17.3.1.8. Australia & New Zealand 17.3.2. By Drug Class 17.3.3. By Product 17.3.4. By Indication 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Product 17.4.4. By Indication 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. India Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Drug Class 17.7.1.2.2. By Product 17.7.1.2.3. By Indication 17.7.1.2.4. By Distribution Channel 17.7.2. Indonesia Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Drug Class 17.7.2.2.2. By Product 17.7.2.2.3. By Indication 17.7.2.2.4. By Distribution Channel 17.7.3. Thailand Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Drug Class 17.7.3.2.2. By Product 17.7.3.2.3. By Indication 17.7.3.2.4. By Distribution Channel 17.7.4. Philippines Market 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Drug Class 17.7.4.2.2. By Product 17.7.4.2.3. By Indication 17.7.4.2.4. By Distribution Channel 17.7.5. Malaysia Market 17.7.5.1. Introduction 17.7.5.2. Market Analysis and Forecast by Market Taxonomy 17.7.5.2.1. By Drug Class 17.7.5.2.2. By Product 17.7.5.2.3. By Indication 17.7.5.2.4. By Distribution Channel 17.7.6. Vietnam Market 17.7.6.1. Introduction 17.7.6.2. Market Analysis and Forecast by Market Taxonomy 17.7.6.2.1. By Drug Class 17.7.6.2.2. By Product 17.7.6.2.3. By Indication 17.7.6.2.4. By Distribution Channel 17.7.7. Australia & New Zealand Market 17.7.7.1. Introduction 17.7.7.2. Market Analysis and Forecast by Market Taxonomy 17.7.7.2.1. By Drug Class 17.7.7.2.2. By Product 17.7.7.2.3. By Indication 17.7.7.2.4. By Distribution Channel 18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Japan 18.3.1.2. China 18.3.1.3. South Korea 18.3.2. By Drug Class 18.3.3. By Product 18.3.4. By Indication 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Product 18.4.4. By Indication 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. Japan Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Drug Class 18.7.1.2.2. By Product 18.7.1.2.3. By Indication 18.7.1.2.4. By Distribution Channel 18.7.2. China Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Drug Class 18.7.2.2.2. By Product 18.7.2.2.3. By Indication 18.7.2.2.4. By Distribution Channel 18.7.3. South Korea Market 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Drug Class 18.7.3.2.2. By Product 18.7.3.2.3. By Indication 18.7.3.2.4. By Distribution Channel 19. Central Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Drug Class 19.3.2. By Product 19.3.3. By Indication 19.3.4. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Drug Class 19.4.2. By Product 19.4.3. By Indication 19.4.4. By Distribution Channel 19.5. Market Trends 19.6. Drivers and Restraints - Impact Analysis 20. Russia & Belarus Market Analysis 2018 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Drug Class 20.3.2. By Product 20.3.3. By Indication 20.3.4. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Drug Class 20.4.2. By Product 20.4.3. By Indication 20.4.4. By Distribution Channel 20.5. Market Trends 20.6. Drivers and Restraints - Impact Analysis 21. Balkan & Baltic Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Drug Class 21.3.2. By Product 21.3.3. By Indication 21.3.4. By Distribution Channel 21.4. Market Attractiveness Analysis 21.4.1. By Drug Class 21.4.2. By Product 21.4.3. By Indication 21.4.4. By Distribution Channel 21.5. Market Trends 21.6. Drivers and Restraints - Impact Analysis 22. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 22.1. Introduction 22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 22.3.1. By Country 22.3.1.1. GCC Countries 22.3.1.2. Kingdom of Saudi Arabia 22.3.1.3. Türkiye 22.3.1.4. Northern Africa 22.3.1.5. South Africa 22.3.1.6. Israel 22.3.2. By Drug Class 22.3.3. By Product 22.3.4. By Indication 22.3.5. By Distribution Channel 22.4. Market Attractiveness Analysis 22.4.1. By Country 22.4.2. By Drug Class 22.4.3. By Product 22.4.4. By Indication 22.4.5. By Distribution Channel 22.5. Market Trends 22.6. Drivers and Restraints - Impact Analysis 22.7. Country Level Analysis & Forecast 22.7.1. GCC Countries Market 22.7.1.1. Introduction 22.7.1.2. Market Analysis and Forecast by Market Taxonomy 22.7.1.2.1. By Drug Class 22.7.1.2.2. By Product 22.7.1.2.3. By Indication 22.7.1.2.4. By Distribution Channel 22.7.2. Kingdom of Saudi Arabia Market 22.7.2.1. Introduction 22.7.2.2. Market Analysis and Forecast by Market Taxonomy 22.7.2.2.1. By Drug Class 22.7.2.2.2. By Product 22.7.2.2.3. By Indication 22.7.2.2.4. By Distribution Channel 22.7.3. Türkiye Market 22.7.3.1. Introduction 22.7.3.2. Market Analysis and Forecast by Market Taxonomy 22.7.3.2.1. By Drug Class 22.7.3.2.2. By Product 22.7.3.2.3. By Indication 22.7.3.2.4. By Distribution Channel 22.7.4. Northern Africa Market 22.7.4.1. Introduction 22.7.4.2. Market Analysis and Forecast by Market Taxonomy 22.7.4.2.1. By Drug Class 22.7.4.2.2. By Product 22.7.4.2.3. By Indication 22.7.4.2.4. By Distribution Channel 22.7.5. South Africa Market 22.7.5.1. Introduction 22.7.5.2. Market Analysis and Forecast by Market Taxonomy 22.7.5.2.1. By Drug Class 22.7.5.2.2. By Product 22.7.5.2.3. By Indication 22.7.5.2.4. By Distribution Channel 22.7.6. Israel Market 22.7.6.1. Introduction 22.7.6.2. Market Analysis and Forecast by Market Taxonomy 22.7.6.2.1. By Drug Class 22.7.6.2.2. By Product 22.7.6.2.3. By Indication 22.7.6.2.4. By Distribution Channel 23. Market Structure Analysis 23.1. Market Analysis by Tier of Companies 23.2. Market Share Analysis of Top Players (%), 2020-2033 23.3. Market Share Analysis, 2022 24. Competition Analysis 24.1. Competition Dashboard 24.2. Key Development Analysis 24.3. Branding and Promotional Strategies 24.4. Competition Deep Dive 24.4.1. AbbVie Inc. (Allergan plc) 24.4.1.1. Overview 24.4.1.2. Product Portfolio 24.4.1.3. Sales Footprint 24.4.1.4. Key Financials 24.4.1.5. Key Developments 24.4.1.6. SWOT Analysis 24.4.1.7. Strategy Overview 24.4.1.7.1. Marketing Strategy 24.4.1.7.2. Product Strategy 24.4.1.7.3. Channel Strategy 24.4.2. Bristol Myers Squibb Co. 24.4.2.1. Overview 24.4.2.2. Product Portfolio 24.4.2.3. Sales Footprint 24.4.2.4. Key Financials 24.4.2.5. Key Developments 24.4.2.6. SWOT Analysis 24.4.2.7. Strategy Overview 24.4.2.7.1. Marketing Strategy 24.4.2.7.2. Product Strategy 24.4.2.7.3. Channel Strategy 24.4.3. Sanofi S.A. 24.4.3.1. Overview 24.4.3.2. Product Portfolio 24.4.3.3. Sales Footprint 24.4.3.4. Key Financials 24.4.3.5. Key Developments 24.4.3.6. SWOT Analysis 24.4.3.7. Strategy Overview 24.4.3.7.1. Marketing Strategy 24.4.3.7.2. Product Strategy 24.4.3.7.3. Channel Strategy 24.4.4. Boehringer Ingelheim International GmbH 24.4.4.1. Overview 24.4.4.2. Product Portfolio 24.4.4.3. Sales Footprint 24.4.4.4. Key Financials 24.4.4.5. Key Developments 24.4.4.6. SWOT Analysis 24.4.4.7. Strategy Overview 24.4.4.7.1. Marketing Strategy 24.4.4.7.2. Product Strategy 24.4.4.7.3. Channel Strategy 24.4.5. Pfizer Inc. 24.4.5.1. Overview 24.4.5.2. Product Portfolio 24.4.5.3. Sales Footprint 24.4.5.4. Key Financials 24.4.5.5. Key Developments 24.4.5.6. SWOT Analysis 24.4.5.7. Strategy Overview 24.4.5.7.1. Marketing Strategy 24.4.5.7.2. Product Strategy 24.4.5.7.3. Channel Strategy 24.4.6. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) 24.4.6.1. Overview 24.4.6.2. Product Portfolio 24.4.6.3. Sales Footprint 24.4.6.4. Key Financials 24.4.6.5. Key Developments 24.4.6.6. SWOT Analysis 24.4.6.7. Strategy Overview 24.4.6.7.1. Marketing Strategy 24.4.6.7.2. Product Strategy 24.4.6.7.3. Channel Strategy 24.4.7. GSK plc. 24.4.7.1. Overview 24.4.7.2. Product Portfolio 24.4.7.3. Sales Footprint 24.4.7.4. Key Financials 24.4.7.5. Key Developments 24.4.7.6. SWOT Analysis 24.4.7.7. Strategy Overview 24.4.7.7.1. Marketing Strategy 24.4.7.7.2. Product Strategy 24.4.7.7.3. Channel Strategy 24.4.8. Abbott Laboratories, Inc. 24.4.8.1. Overview 24.4.8.2. Product Portfolio 24.4.8.3. Sales Footprint 24.4.8.4. Key Financials 24.4.8.5. Key Developments 24.4.8.6. SWOT Analysis 24.4.8.7. Strategy Overview 24.4.8.7.1. Marketing Strategy 24.4.8.7.2. Product Strategy 24.4.8.7.3. Channel Strategy 24.4.9. Novartis AG 24.4.9.1. Overview 24.4.9.2. Product Portfolio 24.4.9.3. Sales Footprint 24.4.9.4. Key Financials 24.4.9.5. Key Developments 24.4.9.6. SWOT Analysis 24.4.9.7. Strategy Overview 24.4.9.7.1. Marketing Strategy 24.4.9.7.2. Product Strategy 24.4.9.7.3. Channel Strategy 24.4.10. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) 24.4.10.1. Overview 24.4.10.2. Product Portfolio 24.4.10.3. Sales Footprint 24.4.10.4. Key Financials 24.4.10.5. Key Developments 24.4.10.6. SWOT Analysis 24.4.10.7. Strategy Overview 24.4.10.7.1. Marketing Strategy 24.4.10.7.2. Product Strategy 24.4.10.7.3. Channel Strategy 24.4.11. Sun Pharmaceutical Industries Ltd. 24.4.11.1. Overview 24.4.11.2. Product Portfolio 24.4.11.3. Sales Footprint 24.4.11.4. Key Financials 24.4.11.5. Key Developments 24.4.11.6. SWOT Analysis 24.4.11.7. Strategy Overview 24.4.11.7.1. Marketing Strategy 24.4.11.7.2. Product Strategy 24.4.11.7.3. Channel Strategy 24.4.12. Teva Pharmaceuticals Ltd. 24.4.12.1. Overview 24.4.12.2. Product Portfolio 24.4.12.3. Sales Footprint 24.4.12.4. Key Financials 24.4.12.5. Key Developments 24.4.12.6. SWOT Analysis 24.4.12.7. Strategy Overview 24.4.12.7.1. Marketing Strategy 24.4.12.7.2. Product Strategy 24.4.12.7.3. Channel Strategy 24.4.13. Mallinckrodt Pharmaceuticals 24.4.13.1. Overview 24.4.13.2. Product Portfolio 24.4.13.3. Sales Footprint 24.4.13.4. Key Financials 24.4.13.5. Key Developments 24.4.13.6. SWOT Analysis 24.4.13.7. Strategy Overview 24.4.13.7.1. Marketing Strategy 24.4.13.7.2. Product Strategy 24.4.13.7.3. Channel Strategy 24.4.14. Endo Pharmaceuticals Inc. 24.4.14.1. Overview 24.4.14.2. Product Portfolio 24.4.14.3. Sales Footprint 24.4.14.4. Key Financials 24.4.14.5. Key Developments 24.4.14.6. SWOT Analysis 24.4.14.7. Strategy Overview 24.4.14.7.1. Marketing Strategy 24.4.14.7.2. Product Strategy 24.4.14.7.3. Channel Strategy 24.4.15. Bayer AG 24.4.15.1. Overview 24.4.15.2. Product Portfolio 24.4.15.3. Sales Footprint 24.4.15.4. Key Financials 24.4.15.5. Key Developments 24.4.15.6. SWOT Analysis 24.4.15.7. Strategy Overview 24.4.15.7.1. Marketing Strategy 24.4.15.7.2. Product Strategy 24.4.15.7.3. Channel Strategy 24.4.16. F. Hoffmann-La Roche Ltd. 24.4.16.1. Overview 24.4.16.2. Product Portfolio 24.4.16.3. Sales Footprint 24.4.16.4. Key Financials 24.4.16.5. Key Developments 24.4.16.6. SWOT Analysis 24.4.16.7. Strategy Overview 24.4.16.7.1. Marketing Strategy 24.4.16.7.2. Product Strategy 24.4.16.7.3. Channel Strategy 24.4.17. Procter & Gamble 24.4.17.1. Overview 24.4.17.2. Product Portfolio 24.4.17.3. Sales Footprint 24.4.17.4. Key Financials 24.4.17.5. Key Developments 24.4.17.6. SWOT Analysis 24.4.17.7. Strategy Overview 24.4.17.7.1. Marketing Strategy 24.4.17.7.2. Product Strategy 24.4.17.7.3. Channel Strategy 24.4.18. AstraZeneca 24.4.18.1. Overview 24.4.18.2. Product Portfolio 24.4.18.3. Sales Footprint 24.4.18.4. Key Financials 24.4.18.5. Key Developments 24.4.18.6. SWOT Analysis 24.4.18.7. Strategy Overview 24.4.18.7.1. Marketing Strategy 24.4.18.7.2. Product Strategy 24.4.18.7.3. Channel Strategy 24.4.19. Cardinal Health 24.4.19.1. Overview 24.4.19.2. Product Portfolio 24.4.19.3. Sales Footprint 24.4.19.4. Key Financials 24.4.19.5. Key Developments 24.4.19.6. SWOT Analysis 24.4.19.7. Strategy Overview 24.4.19.7.1. Marketing Strategy 24.4.19.7.2. Product Strategy 24.4.19.7.3. Channel Strategy 24.4.20. Perrigo Company Plc. 24.4.20.1. Overview 24.4.20.2. Product Portfolio 24.4.20.3. Sales Footprint 24.4.20.4. Key Financials 24.4.20.5. Key Developments 24.4.20.6. SWOT Analysis 24.4.20.7. Strategy Overview 24.4.20.7.1. Marketing Strategy 24.4.20.7.2. Product Strategy 24.4.20.7.3. Channel Strategy 24.4.21. Bausch Health Companies Inc. 24.4.21.1. Overview 24.4.21.2. Product Portfolio 24.4.21.3. Sales Footprint 24.4.21.4. Key Financials 24.4.21.5. Key Developments 24.4.21.6. SWOT Analysis 24.4.21.7. Strategy Overview 24.4.21.7.1. Marketing Strategy 24.4.21.7.2. Product Strategy 24.4.21.7.3. Channel Strategy 24.4.22. Viatris 24.4.22.1. Overview 24.4.22.2. Product Portfolio 24.4.22.3. Sales Footprint 24.4.22.4. Key Financials 24.4.22.5. Key Developments 24.4.22.6. SWOT Analysis 24.4.22.7. Strategy Overview 24.4.22.7.1. Marketing Strategy 24.4.22.7.2. Product Strategy 24.4.22.7.3. Channel Strategy 24.4.23. Amillioneal Pharmaceuticals 24.4.23.1. Overview 24.4.23.2. Product Portfolio 24.4.23.3. Sales Footprint 24.4.23.4. Key Financials 24.4.23.5. Key Developments 24.4.23.6. SWOT Analysis 24.4.23.7. Strategy Overview 24.4.23.7.1. Marketing Strategy 24.4.23.7.2. Product Strategy 24.4.23.7.3. Channel Strategy 24.4.24. Purdue Pharmaceuticals L.P. 24.4.24.1. Overview 24.4.24.2. Product Portfolio 24.4.24.3. Sales Footprint 24.4.24.4. Key Financials 24.4.24.5. Key Developments 24.4.24.6. SWOT Analysis 24.4.24.7. Strategy Overview 24.4.24.7.1. Marketing Strategy 24.4.24.7.2. Product Strategy 24.4.24.7.3. Channel Strategy 25. Assumptions and Acronyms Used 26. Research Methodology
Explore Healthcare Insights
View Reports
Pain Therapeutic Injectables Market
